Gilbert Mchantaf

Gilbert Mchantaf

Auto-generated profile, based on publicly available information

Gilbert Mchantaf

CHU d'Orléans, Virologie Orléans France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
VBVanda Barakett-Hamade
Vanda Barakett-Hamade
JGJean Pierre Ghayad
Jean Pierre Ghayad
GMGilbert Mchantaf
Gilbert Mchantaf
GSGhassan Sleilaty
Ghassan Sleilaty

28 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ADAgnieszka Dorman
Agnieszka Dorman
MBMaryam Bendoumou
Maryam Bendoumou
AVAurelija Valaitienė
Aurelija Valaitienė
JWJakub Wadas
Jakub Wadas
HAHaider Ali
Haider Ali
AKAnna Kula
Anna Kula
HIV-1 latency is mainly characterized at transcriptional level, and little is known about post-transcriptional mechanisms and their contribution to reactivation. The viral protein Rev controls the nucleocytoplasmic export of unspliced and singly-spliced RNA that is central to proviral replication-competence and is therefore a prerequisite for efficient viral reactivation during the “shock-and-kill” cure therapy. Here we show that during infection and reactivation, unspliced HIV-1 RNA is a subject to complex and dynamic regulation by the Rev cofactor MATR3 and the MTR4 cofactor of the nuclear exosome. MATR3 and MTR4 coexist in the same ribonucleoprotein complex functioning to either maintain or degrade the RNA, respectively, with Rev orchestrating this regulatory switch. Moreover, we provide evidence of nuclear retention of unspliced HIV-1 RNA in ex vivo cultures from 22 ART-treated people with HIV, highlighting a reversible post-transcriptional block to viral RNA nucleocytoplasmic export that is relevant to the design of curative interventions.

9 December 2023 in Journal of Virus Eradication
Verified
Journal Article
Open access
GMGilbert Mchantaf
Gilbert Mchantaf
ACAntoine Cheret
Antoine Cheret
AMAdeline Melard
Adeline Melard
AEAsma Essat
Asma Essat
EGElise Gardiennet
Elise Gardiennet
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
Understanding factors affecting the size and the evolution of the HIV reservoir is essential for the development of curative strategies. This study aimed to assess the impact of antiretroviral therapy (ART) initiated during primary infection (PHI) vs chronic infection (CHI) on the levels and dynamics of integrated HIV-1 DNA, a biomarker of viral persistence. Integrated and total HIV-1-DNA were measured in the blood of 92 patients treated during PHI (early group) and 41 during CHI (deferred group), at diagnosis, ART initiation, and 12–24 months on treatment. On ART, detectable (>1.78 log10 copies/106 PBMCs) integrated HIV-1 DNA levels were significantly lower in the early vs deferred group (2.99 log10vs 3.29 log10,p = 0.005). The proportion of undetectable integrated HIV-1 DNA tended to be higher in the early group vs deferred group (61 % vs 46 %; p = 0.133). Treatment initiated at PHI limits the levels of integrated HIV-1 DNA in blood. However, initiating treatment at CHI does not allow reaching such low levels in most patients, probably because the stable proviruses at that stage are present in the less prone to elimination long-lived cells. Thus, early ART could provide an opportunity to preparing for functional cure and eradication strategies.

23 December 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
GMGilbert Mchantaf
Gilbert Mchantaf
ACAntoine Chaillon
Antoine Chaillon
Caroline CharreCaroline Charre
Caroline Charre
AMAdeline Melard
Adeline Melard
EGElise Gardiennet
Elise Gardiennet
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
Background: To better understand factors associated with virologic response, we retrospectively characterized the HIV proviruses of 7 people with HIV who received long-acting cabotegravir/rilpivirine (CAB/RPV-LA) and were selected according to the following criteria: virologic control achieved despite a history of viral replication on 1 or both corresponding antiretroviral classes (n = 6) and virologic failure (VF) after CAB/RPV-LA initiation (n = 1). Methods: Last available blood samples before the initiation of CAB/RPV-LA were analyzed retrospectively. Near full-length HIV DNA genome haplotypes were inferred from Nanopore sequencing by the in vivo Genome Diversity Analyzer to search for archived drug resistance mutations (DRMs) and evaluate the frequency and intactness of proviruses harboring DRMs. Results: Archived DRMs including G-to-A mutations were found in samples from 3 patients who maintained virologic control. Genomes harboring DRMs were majorly in minority variants (<20%) and were defective in all cases except for 1 participant. In this participant, intact genomes with the H221Y mutation on reverse transcriptase were detected representing 11 copies per 106 peripheral blood mononuclear cells. The other mutations observed in the participants of the study resulted most likely from hypermutations. The patient with VF presented archived mutations, all associated with defects. Other factors could explain this VF. Conclusions: Our findings highlight the difficulty in interpreting the clinical significance of DRMs when detected in proviral DNA and the need to filter out hypermutated sequences. Detected DRMs could be harbored by defective archived genomes unlikely to contribute to treatment failure.

27 January 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
GMGilbert Mchantaf
Gilbert Mchantaf
AMAdeline Melard
Adeline Melard
KSKévin Da Silva
Kévin Da Silva
EGElise Gardiennet
Elise Gardiennet
ACAntoine Chaillon
Antoine Chaillon
VAVéronique Avettand-Fenoel
Véronique Avettand-Fenoel
Background Relatively few studies have investigated HIV-1 persistence in tissues, especially in healthy people-living-with-HIV-1 (PLWH) on a successful antiretroviral regimen containing second generation integrase inhibitors. Methods In the ANRS EP64 DOLUVOIR, we explore HIV-1 persistence in five accessible anatomical sites in 20 PLWH on an efficient first-line ART regimen containing dolutegravir with virological load <50 copies/mL: PBMCs, rectum, adipose tissue, lymph node and sperm. We quantify total HIV-DNA and cell-associated HIV-1 RNA in different compartments. We sequence HIV-1 DNA for searching drug resistance mutations (DRM) (in RT and INT) and for studying HIV diversity within tissues (ENV). Intact proviral DNA is estimated in PBMCs with an adapted IPDA assay. Results Broad ranges of total HIV-DNA and transcripts levels are detected in lymph nodes, PBMCs, adipose tissue and rectum with the highest levels being found in lymph nodes (2.77 log copies HIV-1-DNA/106 cells and 1.50 log copies of HIV-1 cell-associated-RNA/µg RNA). HIV-1 DNA is undetected in all sperm samples (n = 19) except for one (1.52 log copies HIV-1-DNA/106 cells). No difference is noted between the diversity in the four compartments. DRMs to the current regimen are found archived in compartments of six participants. Only two major DRMs to dolutegravir (G118R and R263K) are found archived in two participants. They are the results of APOBEC hypermutations. Conclusions Despite ongoing transcriptional activity, persistence of HIV-1 in deep tissues is not associated with the selection of DRMs to dolutegravir on intact proviruses. Our results suggest that the detectable transcriptional activity stems predominantly from defective proviral DNA.

1 August 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
VBVanda Barakett-Hamadé
Vanda Barakett-Hamadé
GMGilbert Mchantaf
Gilbert Mchantaf
GSGhassan Sleilaty
Ghassan Sleilaty